Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P57771
UPID:
RGS8_HUMAN
Alternative names:
-
Alternative UPACC:
P57771; B4DGL9; Q3SYD2
Background:
Regulator of G-protein signaling 8 (RGS8) plays a pivotal role in modulating G protein-coupled receptor (GPCR) signaling pathways. Specifically, it regulates signaling cascades initiated by muscarinic acetylcholine receptor CHRM2 and dopamine receptor DRD2. RGS8 achieves this by enhancing the GTPase activity of G protein alpha subunits, leading them to their inactive GDP-bound form, thereby inhibiting signal transduction. Additionally, it influences the activity of potassium channels activated in response to DRD2 and CHRM2 signaling.
Therapeutic significance:
Understanding the role of Regulator of G-protein signaling 8 could open doors to potential therapeutic strategies.